Farmacia Hospitalaria y Farmacogenómica

Galar, A; Valerio, M; Munoz, P; Alcala, L; Garcia-Gonzalez, X; Burillo, A; Sanjurjo, M; Grau, S; Bouza, E.

Systematic Therapeutic Drug Monitoring for Linezolid: Variability and Clinical Impact

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2017; 61(10): Nº de citas: 21 [doi:10.1128/AAC.00687-17]

Pellicer, M; Garcia-Gonzalez, X; Garcia, MI; Blanco, C; Garcia-Alfonso, P; Robles, L; Gravalos, C; Rueda, D; Martinez, J; Pachon, V; Longo, F; Martinez, V; Iglesias, I; Salvador, S; Sanjurjo, M; Lopez-Fernandez, LA.

Use of exome sequencing to determine the full profile of genetic variants in the fluoropyrimidine pathway in colorectal cancer patients affected by severe toxicity

PHARMACOGENOMICS. 2017; 18(13): 1215-1223 Nº de citas: 11 [doi:10.2217/pgs-2017-0118]

Chamorro-de-Vega, E; Rodriguez-Gonzalez, CG; Gimenez-Manzorro, A; de Lorenzo-Pinto, A; Iglesias-Peinado, I; Herranz, A; Sanjurjo, M.

Improving pharmacotherapy outcomes in patients with hepatitis C virus; infection treated with direct-acting antivirals: The GRUviC project

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. 2017; 71(8): Nº de citas: 8 [doi:10.1111/ijcp.12988]

Arrabal-Duran, P; Rodriguez-Gonzalez, CG; Chamorro-de-Vega, E; Gijon-Vidaurreta, P; Herranz-Alonso, A; Sanjurjo-Saez, M.

Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96weeks

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. 2017; 71(8): Nº de citas: 9 [doi:10.1111/ijcp.12968]

Laiseca, LB; del Castillo, BT; Jimenez, CR; Manrique-Rodriguez, S; Moreno, JP.

Downbeat nystagmus due to ranitidine in a pediatric patient

EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY. 2017; 21(4): 682-684 Nº de citas: 7 [doi:10.1016/j.ejpn.2017.01.015]

Pellicer, M; Garcia-Gonzalez, X; Garcia, MI; Robles, L; Gravalos, C; Garcia-Alfonso, P; Pachon, V; Longo, F; Martinez, V; Blanco, C; Iglesias, I; Sanjurjo, M; Lopez-Fernandez, LA.

Identification of new SNPs associated with severe toxicity to capecitabine

PHARMACOLOGICAL RESEARCH. 2017; 120: 133-137 Nº de citas: 43 [doi:10.1016/j.phrs.2017.03.021]

Escudero-Vilaplana, V; Ribed, A; Romero-Jimenez, RM; Herranz-Alonso, A; Sanjurjo-Saez, M.

Pharmacotherapy follow-up of key points in the safety of oral antineoplastic agents

EUR J CANCER CARE. 2017; 26(3): Nº de citas: 15 [doi:10.1111/ecc.12463]

Jimenez, RMR; Navarro, CO; Compes, CC.

Polypharmacy and enteral nutrition in patients with complex chronic diseases

NUTRICION HOSPITALARIA. 2017; 34: 57-76 Nº de citas: 12 [doi:10.20960/nh.1240]

Garcia-Lopez, I; Fuentes-Rios, JE; Manrique-Rodriguez, S; Fernandez-Llamazares, CM.

Off-label and unlicensed drug use: Results from a pilot study in a pediatric intensive care unit

ANALES DE PEDIATRIA. 2017; 86(1): 28-36 Nº de citas: 17 [doi:10.1016/j.anpedi.2016.01.026]

Lopez, C; Alcaraz, AJ; Toledo, B; Cortejoso, L; Gil-Ruiz, MA.

Acetazolamide Therapy for Metabolic Alkalosis in Pediatric Intensive Care Patients

PEDIATRIC CRITICAL CARE MEDICINE. 2016; 17(12): 551-558 Nº de citas: 14 [doi:10.1097/PCC.0000000000000971]

Manrique-Rodriguez, S; de la Rubia-Nieto, A; Garcia-Robles, JA; Goicoechea-Diezhandino, M; Gimeno-Blanes, JA; Pernia-Lopez, MS; Pellicer-Franco, C; Sanjurjo-Saez, M.

Individualized therapy in patients with Fabry disease: is it a feasible strategy for rare diseases?

Expert Opinion on Orphan Drugs. 2016; 4(12): 1199-1206 Nº de citas: 1 [doi:10.1080/21678707.2016.1253468]

González-Haba Peña E; Manrique Rodríguez S; Herranz Alonso AM; Pérez Castán P; Moreno Gálvez M; Iglesias Peinado I; Sanjurjo Saez M.

Comparative study of preparation of hazardous drugs with different closed-system drug transfer devices by means of simulation with fluorescein.

FARMACIA HOSPITALARIA. 2016; 40(n06): 496-503 [doi:10.7399/fh.2016.40.6.10607]

Collado-Borrell, R; Escudero-Vilaplana, V; Romero-Jimenez, R; Iglesias-Peinado, I; Herranz-Alonso, A; Sanjurjo-Saez, M.

Oral antineoplastic agent interactions with medicinal plants and food: an issue to take into account

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2016; 142(11): 2319-2330 Nº de citas: 36 [doi:10.1007/s00432-016-2190-8]

Chamorro-de-Vega, E; Gimenez-Manzorro, A; Rodriguez-Gonzalez, CG; Escudero-Vilaplana, V; Borrell, RC; Ibanez-Garcia, S; Sainz, EL; Matilla, EL; Lorenzo-Pinto, A; Manrique-Rodriguez, S; Fernandez-Llamazares, CM; Marzal-Alfaro, M; Ribed, A; Jimenez, RMR; Gonzalez, CS; Herranz, A; Sanjurjo, M.

Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice

ANNALS OF PHARMACOTHERAPY. 2016; 50(11): 901-908 Nº de citas: 10 [doi:10.1177/1060028016659306]

de Lorenzo-Pinto, A; Llorente, BP.

Successful Treatment With Bosentan for Digital Ulcers Related to Mixed Cryoglobulinemia: A Case Report

AMERICAN JOURNAL OF THERAPEUTICS. 2016; 23(6): 1942-1943 Nº de citas: 2 [doi:10.1097/MJT.0000000000000384]

Manrique-Rodriguez, S; Sanchez-Galindo, AC; Fernandez-Llamazares, CM; Calvo-Calvo, MM; Carrillo-Alvarez, A; Sanjurjo-Saez, M.

Safe intravenous administration in pediatrics: A 5-year Pediatric Intensive Care Unit experience with smart pumps

Medicina Intensiva. 2016; 40(7): 411-421 Nº de citas: 11 [doi:10.1016/j.medin.2016.01.011]

Pascual-Pascual, SI; Nascimento, A; Fernandez-Llamazares, CM; Medrano-Lopez, C; Villalobos-Pinto, E; Martinez-Moreno, M; Ley, M; Manrique-Rodriguez, S; Blasco-Alonso, J.

Clinical guidelines for infantile-onset Pompe disease

REVISTA DE NEUROLOGIA. 2016; 63(6): 269-279 Nº de citas: 9 [doi:10.33588/rn.6306.2016232]

de Lorenzo-Pinto, A; Gimenez-Manzorro, A; Rodriguez-Gonzalez, CG; Ahumada-Jimenez, A; Herranz-Alonso, A; Marzal-Alfaro, MB; Sanjurjo-Saez, M.

Decreased INR after acenocoumarol, ombitasvir/paritaprevir/ritonavir and dasabuvir co-administration

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS. 2016; 41(4): 444-446 Nº de citas: 3 [doi:10.1111/jcpt.12403]